Bronchiolitis

Bronchiolitis is an acute inflammatory illness of the small airways (bronchioles) within the lung, most commonly affecting infants and young children under two years of age. It is typically caused by a viral infection, leading to inflammation, edema, and excessive mucus production, which obstructs the bronchioles and causes characteristic wheezing, coughing, and respiratory distress.

Bronchiolitis is predominantly caused by viral infections. The most common causative agents include:

• Respiratory Syncytial Virus (RSV): Accounts for 50-80% of cases.


• Rhinovirus


• Human Metapneumovirus


• Parainfluenza Virus


• Adenovirus


• Influenza Virus

The primary site of infection is the epithelial cells lining the small airways. Upon viral entry, the virus replicates within these cells, causing direct cellular damage and necrosis. This triggers a robust inflammatory response, leading to submucosal edema, increased mucus production, and sloughing of necrotic cells. These processes combine to narrow and obstruct the small bronchioles. Airway obstruction results in air trapping and hyperinflation distal to the obstruction, as air can enter but not easily exit the alveoli. This also leads to ventilation-perfusion mismatch, resulting in hypoxemia. In severe cases, complete obstruction can lead to atelectasis.

Bronchiolitis is a highly prevalent seasonal disease, typically occurring during winter and early spring months. It is the leading cause of hospitalization for infants in the United States.

• Age Distribution: Primarily affects infants and young children under two years of age, with a peak incidence between 2 and 6 months of age.


• Gender Distribution: Slightly more common and often more severe in males.


• Prevalence: Nearly all children will have been infected with RSV by age two, with a significant proportion developing bronchiolitis.

• Prematurity (born before 37 weeks gestation)
• Age < 3-6 months
• Underlying cardiopulmonary disease (e.g., congenital heart disease, chronic lung disease of prematurity)
• Immunodeficiency (e.g., HIV, chemotherapy)
• Exposure to tobacco smoke (in utero or passive)
• Crowded living conditions
• Attendance at daycare
• Male gender
• Lack of breastfeeding

A. Early Symptoms

• Rhinorrhea (runny nose)


• Nasal congestion


• Mild cough


• Low-grade fever (often <101°F or 38.3°C)


• Decreased appetite


• Irritability B. Common Symptoms


• Worsening cough


• Tachypnea (rapid breathing)


• Nasal flaring


• Intercostal, subcostal, or supraclavicular retractions (visible pulling in of skin between ribs, below ribs, or above collarbones)


• Wheezing (high-pitched whistling sound during breathing)


• Difficulty feeding due to respiratory distress


• Irritability or lethargy C. Advanced Symptoms


• Severe respiratory distress


• Cyanosis (bluish discoloration of lips or skin due to low oxygen)


• Apnea (pauses in breathing), especially in premature infants or those <2 months


• Significant lethargy or unresponsiveness D. Emergency Symptoms


• Apnea or irregular breathing


• Severe cyanosis


• Profound lethargy or unresponsiveness


• Inability to feed due to respiratory distress


• Signs of dehydration (decreased wet diapers, sunken fontanelle)

• Vital Signs: Tachypnea, tachycardia, fever (mild or absent), hypoxemia (decreased SpO2).
• Inspection: Nasal flaring, grunting, retractions (intercostal, subcostal, supraclavicular), prolonged expiratory phase, hyperinflation of the chest.
• Palpation: Normal fremitus, possibly increased tactile fremitus if atelectasis is present.
• Auscultation: Diffuse inspiratory and expiratory wheezes, crackles (rales), decreased breath sounds in areas of atelectasis.

A. Clinical Assessment
Diagnosis is primarily clinical, based on age, characteristic symptoms (viral prodrome followed by cough, tachypnea, wheezing), and physical examination findings.
B. Laboratory Testing
Generally not required for typical cases; may be used to identify the causative virus or assess severity.
C. Imaging Studies
Chest X-ray is not routinely recommended but may be considered if diagnosis is uncertain or complications are suspected.
D. Functional Tests
Pulse oximetry to assess oxygen saturation is crucial.
E. Biopsy Findings
Not applicable for diagnosis.
F. Genetic Testing
Not applicable for diagnosis.
G. Differential Diagnosis
Distinguished from asthma, foreign body aspiration, pneumonia, pertussis, allergic reaction, and heart failure.

Viral Panel (Respiratory Syncytial Virus, Rhinovirus, etc.)
Type: Nasal Aspirate/Swab/Wash
Purpose: To identify the specific viral pathogen, primarily for epidemiological surveillance, infection control, or in cases of severe illness/immunocompromise.
Expected Findings: Positive for a common respiratory virus (e.g., RSV).
Interpretation: Confirms viral etiology; typically does not alter acute management for uncomplicated bronchiolitis. Pulse Oximetry
Type: Non-invasive monitoring
Purpose: To assess arterial oxygen saturation (SpO2) and monitor for hypoxemia.
Expected Findings: SpO2 <90-92% in moderate to severe cases.
Interpretation: Essential for guiding the need for supplemental oxygen and determining the severity of respiratory compromise. Arterial Blood Gas (ABG)
Type: Blood Test
Purpose: To assess oxygenation, ventilation (CO2 levels), and acid-base status in severe respiratory distress or suspected respiratory failure.
Expected Findings: Hypoxemia, hypercapnia (elevated CO2) in respiratory failure, respiratory acidosis.
Interpretation: Used in critical cases to guide ventilatory support.

Chest X-ray
Purpose: To rule out complications such as pneumonia or pneumothorax, or to consider alternative diagnoses when the clinical picture is atypical.
Typical Findings: Hyperinflation of the lungs, flattening of the diaphragms, peribronchial thickening ("cuffing"), and patchy areas of atelectasis. Consolidation may indicate bacterial pneumonia.
Clinical Importance: Not routinely recommended for the diagnosis of typical bronchiolitis due to characteristic clinical findings and lack of impact on management. However, it can be useful in severe or atypical presentations.

• Asthma: Recurrent wheezing episodes, personal/family history of atopy, older age (>2 years), good response to bronchodilators.
• Pneumonia (viral or bacterial): More localized findings, consolidation on chest X-ray, higher fever, absence of typical bronchiolitis wheezing pattern.
• Foreign Body Aspiration: Sudden onset of coughing/choking, unilateral wheezing, history of exposure to small objects, no viral prodrome.
• Pertussis (Whooping Cough): Characteristic paroxysmal cough followed by an inspiratory "whoop", post-tussive emesis, often no wheezing.
• Congenital Heart Disease with Heart Failure: Murmur, cardiomegaly on chest X-ray, hepatomegaly, absent viral prodrome.
• Cystic Fibrosis: History of meconium ileus, failure to thrive, persistent cough, steatorrhea, positive sweat chloride test.

• Dehydration: Due to decreased oral intake and increased insensible fluid losses from tachypnea.
• Hypoxemia and Respiratory Failure: Requiring supplemental oxygen or ventilatory support.
• Apnea: Especially in premature or very young infants (<2 months).
• Bacterial Superinfection: Otitis media, pneumonia.
• Atelectasis: Collapse of lung segments due to complete airway obstruction.
• Recurrent Wheezing/Asthma: A significant number of children with severe bronchiolitis, particularly RSV, may develop these conditions later in life.

A. Lifestyle Modifications

• Nasal Suctioning: Regular gentle suctioning of nasal passages to clear secretions and improve breathing.


• Hydration: Small, frequent oral feeds; intravenous fluids if oral intake is poor due to respiratory distress.


• Positioning: Elevating the head of the bed or propping the infant up can aid breathing. B. Preventive Measures


• Hand Hygiene: Frequent hand washing to reduce viral transmission.


• Avoid Sick Contacts: Limit exposure of infants to individuals with respiratory infections.


• Avoid Tobacco Smoke Exposure: Eliminate exposure to active or passive smoke.


• Breastfeeding: Provides antibodies and protective factors.


• Palivizumab: A monoclonal antibody given intramuscularly monthly during RSV season to high-risk infants (e.g., premature infants <29 weeks, chronic lung disease, significant congenital heart disease) to prevent severe RSV disease. C. Medical Treatment


• Supportive Care: This is the cornerstone of bronchiolitis management.


• Supplemental Oxygen: Administered to maintain SpO2 >90-92% (target varies by guidelines).


• Fluid Management: Oral or intravenous fluids to prevent dehydration.

• Examples: Albuterol, Levalbuterol.


• Clinical Use: Not routinely recommended due to lack of consistent benefit in typical bronchiolitis; a trial may be considered in infants with a strong history of reactive airway disease or asthma, but discontinued if no clear clinical response.

• Clinical Use: Not recommended for routine use as they have not shown benefit in acute bronchiolitis.

• Clinical Use: Some studies suggest a modest benefit in reducing hospital stay for hospitalized infants, but evidence is conflicting, and it's not universally recommended.

• Airway Management: Ensure a patent airway; suctioning.


• Oxygenation: High-flow nasal cannula (HFNC), CPAP (continuous positive airway pressure), or mechanical ventilation for severe respiratory failure.


• Fluid Resuscitation: For dehydration and shock.


• Monitoring: Continuous cardiorespiratory and pulse oximetry monitoring.

The prognosis for most infants with bronchiolitis is excellent. It is typically a self-limiting illness lasting 2-3 weeks, with the most severe symptoms resolving within 5-7 days. Most infants recover fully without long-term complications. However, some children, particularly those hospitalized for severe bronchiolitis, may experience recurrent wheezing or develop asthma later in childhood.

Primary Prevention: Frequent hand washing.

• Avoidance of close contact with sick individuals.


• Avoidance of tobacco smoke exposure.


• Exclusive breastfeeding for the first 6 months.


• Annual influenza vaccination for eligible children and household contacts.

The following homeopathic remedies have been historically indicated for symptoms associated with Bronchiolitis. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Bronchiolitis.